Crossmark

Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury

Crossref DOI link: https://doi.org/10.1186/s40425-019-0502-7

Published Online: 2019-02-06

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Abu-Sbeih, Hamzah

Tang, Tenglong

Lu, Yang

Thirumurthi, Selvi

Altan, Mehmet

Jazaeri, Amir A.

Dadu, Ramona

Coronel, Emmanuel

Wang, Yinghong https://orcid.org/0000-0002-5148-6130
More Information

Article History

Received: 16 October 2018

Accepted: 9 January 2019

First Online: 6 February 2019

Ethics approval and consent to participate

: This retrospective, single-center study was approved by the Institutional Review Board at The University of Texas MD Anderson Cancer Center.

: This study was granted waiver for consent.

: Dr. Amir A Jazaeri received research funding from Iovance, AstraZeneca, Bristol-Myers Squibb, Pfizer, Lilly, served on Advisory Board for Iovance, Aravive, Almac, and Data Safety Monitoring Board for Genetech. Dr. Ramona Dadu received research funding from Merck, Eisai, AstraZeneca, and served on Advisory Board for Bristol-Myers Squibb. The other authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.